The 2025 NF Conference brings together researchers, patients, and advocates to discuss progress and future prospects in NF treatment and discovery. The event features keynotes on gene therapy, regulatory reform, and next-generation pain treatments.
The Children's Tumor Foundation has announced revised diagnostic criteria for neurofibromatosis type 1 (NF1), which aim to improve the accuracy and earlier diagnosis of the condition. The updated criteria also cover Legius syndrome and mosaic NF, with further updates expected for NF2 and schwannomatosis.
A recent study published in Neuro-Oncology has made significant progress in understanding low-grade gliomas (LGG) in NF patients, which affect nearly a third of those with NF1. The research collaboration between NF experts and LGG specialists aims to develop new therapeutic strategies for these patients.
The Children's Tumor Foundation has launched the NF2 Accelerator Initiative, a three-year research effort to bring active NF2 treatments to patients. The initiative focuses on expanding the clinical drug pipeline, improving drug selection through innovative testing models, and developing gene therapy options.
Researchers have discovered that nerve fibers and associated Schwann cells are the origin of severely disfiguring neurofibromas in NF1 patients. The study found micro-lesions containing these nerve fibers and cells proliferate to form the bulk of the disfiguring neurofibromas.
Recent research by Children's Tumor Foundation advances understanding of brain tumors affecting neurofibromatosis patients. Two large-scale studies have identified genetic, epigenetic, and metabolic alterations in NF1 gliomas, paving the way for targeted therapies.
The Synodos for NF2 consortium published its first set of results, showing that drug combination therapies are effective in treating schwannomas and meningiomas. The team integrated innovative research approaches to analyze gene and protein expression, finding that different drugs are likely needed to treat these two tumor types.